Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR).
COVID-19
/ diagnosis
COVID-19 Testing
Clinical Laboratory Techniques
/ methods
Humans
Pandemics
RNA, Viral
/ analysis
RNA-Directed DNA Polymerase
/ genetics
Real-Time Polymerase Chain Reaction
/ methods
Reverse Transcriptase Polymerase Chain Reaction
SARS-CoV-2
/ genetics
Sensitivity and Specificity
RT-qPCR
SARS-CoV-2 diagnosis
biological sampling
cycle threshold
Journal
Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
16
11
2021
revised:
12
04
2022
accepted:
29
04
2022
pubmed:
2
7
2022
medline:
17
8
2022
entrez:
1
7
2022
Statut:
ppublish
Résumé
During the COVID-19 pandemic, the reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR) assay has been the primary method of diagnosis of SARS-CoV-2 infection. However, RT-qPCR assay interpretation can be ambiguous with no universal absolute cut-off value to determine sample positivity, which particularly complicates the analysis of samples with high Ct values, or weak positives. Therefore, we sought to analyse factors associated with weak positive SARS-CoV-2 diagnosis. We analysed sample data associated with all positive SARS-CoV-2 RT-qPCR diagnostic tests performed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in Melbourne, Australia, during the Victorian first wave (22 January 2020-30 May 2020). A subset of samples was screened for the presence of host DNA and RNA using qPCR assays for CCR5 and 18S, respectively. Assays targeting the viral RNA-dependent RNA polymerase (RdRp) had higher Ct values than assays targeting the viral N and E genes. Weak positives were not associated with the age or sex of individuals' samples nor with reduced levels of host DNA and RNA. We observed a relationship between Ct value and time post-SARS-CoV-2 diagnosis. High Ct value or weak positive SARS-CoV-2 was not associated with any particular bias including poor biological sampling.
Identifiants
pubmed: 35778288
pii: S0031-3025(22)00171-4
doi: 10.1016/j.pathol.2022.04.001
pmc: PMC9239708
pii:
doi:
Substances chimiques
RNA, Viral
0
RNA-Directed DNA Polymerase
EC 2.7.7.49
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
623-628Informations de copyright
Copyright © 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.
Références
Med J Aust. 2020 Jun;212(10):459-462
pubmed: 32237278
Lancet HIV. 2015 Dec;2(12):e520-9
pubmed: 26614966
Ann Am Thorac Soc. 2021 May;18(5):900-903
pubmed: 33119425
Euro Surveill. 2020 May;25(21):
pubmed: 32489175
Nat Microbiol. 2020 Oct;5(10):1299-1305
pubmed: 32651556
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Transl Med. 2021 Jan 7;19(1):32
pubmed: 33413422
Lancet Reg Health Eur. 2021 Aug;7:100150
pubmed: 34250518
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
Nat Commun. 2022 Jan 27;13(1):532
pubmed: 35087035
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
Clin Chem. 2020 Jun 1;66(6):794-801
pubmed: 32246822
Mol Med. 2021 Mar 26;27(1):30
pubmed: 33771097
PLoS Biol. 2020 Dec 15;18(12):e3001030
pubmed: 33320856
Infect Dis Ther. 2020 Sep;9(3):573-586
pubmed: 32725536
Virol Sin. 2020 Dec;35(6):758-767
pubmed: 32749593
Heliyon. 2020 Oct;6(10):e05143
pubmed: 33024851
Clin Infect Dis. 2020 Dec 17;71(10):2663-2666
pubmed: 32442256
PLoS Pathog. 2014 Nov 13;10(10):e1004473
pubmed: 25393648
J Infect Dis. 2020 Aug 17;222(6):899-902
pubmed: 32594170
PLoS One. 2020 Nov 18;15(11):e0241469
pubmed: 33206690
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
EBioMedicine. 2021 Aug;70:103525
pubmed: 34392148
J Med Virol. 2021 Oct;93(10):5917-5923
pubmed: 34139026
PLoS Biol. 2020 Sep 8;18(9):e3000849
pubmed: 32898168
Lancet HIV. 2018 May;5(5):e221-e230
pubmed: 29643011
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
Pathology. 2020 Dec;52(7):796-800
pubmed: 33036772
J Clin Med. 2020 Sep 10;9(9):
pubmed: 32927798
J Clin Virol. 2004 Jul;30(3):214-7
pubmed: 15135737
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
J Virol Methods. 2020 Dec;286:113974
pubmed: 32949663
J Clin Med. 2021 Jan 15;10(2):
pubmed: 33467628
Eur J Clin Microbiol Infect Dis. 2020 Jun;39(6):1059-1061
pubmed: 32342252
Front Immunol. 2018 Jan 05;8:1908
pubmed: 29379499
Nucleic Acids Res. 2012 Aug;40(15):e113
pubmed: 22544708
Eur Respir J. 2021 Jul 20;58(1):
pubmed: 34172468